Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial

Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some patients experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations and reduced inha...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Manuel J., Stollfuß, Barbara, Roitenberg, Alexander, Kleinjung, Frank, Graeff , Valentin, Berghaus, Sabine, Müller, Christian, Ghofrani, Hossein-Ardeschir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128078/
https://www.ncbi.nlm.nih.gov/pubmed/30124140
http://dx.doi.org/10.1177/2045894018798921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128078/
https://www.ncbi.nlm.nih.gov/pubmed/30124140
http://dx.doi.org/10.1177/2045894018798921

Ejemplares similares